Journal article

Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.

Adelle S Jee, Robert Sheehy, Peter Hopkins, Tamera J Corte, Christopher Grainge, Lauren K Troy, Karen Symons, Lissa M Spencer, Paul N Reynolds, Sally Chapman, Sally de Boer, Taryn Reddy, Anne E Holland, Daniel C Chambers, Ian N Glaspole, Helen E Jo, Jane F Bleasel, Jeremy P Wrobel, Leona Dowman, Matthew JS Parker Show all

Respirology | Published : 2021

Abstract

Pulmonary complications in CTD are common and can involve the interstitium, airways, pleura and pulmonary vasculature. ILD can occur in all CTD (CTD-ILD), and may vary from limited, non-progressive lung involvement, to fulminant, life-threatening disease. Given the potential for major adverse outcomes in CTD-ILD, accurate diagnosis, assessment and careful consideration of therapeutic intervention are a priority. Limited data are available to guide management decisions in CTD-ILD. Autoimmune-mediated pulmonary inflammation is considered a key pathobiological pathway in these disorders, and immunosuppressive therapy is generally regarded the cornerstone of treatment for severe and/or progressi..

View full abstract